Background Aortic valve replacement is the gold standard treatment for severe symptomatic aortic valve disease. Recently, aortic valve reconstruction surgery (Ozaki procedure) emerges as a surgical alternative with good results in the medium term. Methods We retrospectively analyzed 38 patients who underwent aortic valve reconstruction surgery between January 2018 and June 2020 in a national reference center in Lima, Peru. The median age was 62 years, interquartile range 25. The main indication for surgery was aortic valve stenosis (63.1%), in most cases due to bicuspid valve (19 patients, 50%). Twenty-two (58%) patients had another pathology with surgical indication associated to AV disease, 8(21%) had dilatation of the ascending aorta with indication for replacement. Results One in-hospital death occurred (1/38, 2.6%) due to perioperative myocardial infarction. There was a significant reduction in the medians of the peak (66mmHg, CI95%=52.5-81.3 vs 15mmHg, CI95%=12.1-17.5, p<0.0001) and mean (41mmHg CI95%=31.8-50.1 vs 8mmHg, CI95%=6.0-9.6, p<0.0001) aortic valve gradients when we compared baseline characteristics with first 30-days results. In an average of 19 (±8.9) months of follow-up, survival, reoperation-free survival for valve dysfunction, and survival free of AV insufficiency> II were 94.6%, 94.6% y 91.7%, respectively. Significant reduction in the medians of the peak (66mmHg, CI95%=52.5-81.3 vs 14mmHg, CI95%=10.9-17.6, p<0.0001) and mean (41mmHg CI95%=31.8-50.1 vs 7mmHg, CI95%=5.2-9.1, p<0.0001) aortic valve gradients were maintained. Conclusions Mid-term outcome follow-up of aortic valve reconstruction surgery showed optimal results in term of mortality, reoperation free survival and hemodynamic characteristics of the neo-aortic valve.

Background: Heart transplantations are ideal for most patients with end-stage heart failure refractory to medical treatment. The transplantation program at the Peruvian National Heart Institute started with a 10-year-continuity in 2010. Objective: To report the results of a 10-year heart transplantation experience at the Peruvian National Heart Institute. Methods: We studied 83 patients who underwent orthotopic heart transplantation at a single center between January 2010 and December 2019. The recipients’ profiles and survival were analyzed according to sex and age group, ensuring the information’s confidentiality. Results: The recipients’ mean age was 41.2 ± 17 years, 88% were adult, and 68.7% were male. The main indications for transplantation were idiopathic dilated cardiomyopathy. 85.5% of recipients were clinically categorized as INTERMACS Profile 1 to 3 before transplantation. There was a significant difference between sexes regarding the preoperative left ventricular ejection fraction and between age groups regarding the waiting time. The average ischemia time was 3.1 hours, operating time was 6.1 hours, cardiopulmonary bypass time was 3 hours, and aortic cross-clamp time was 1.7 hours. The principal early postoperative complications were hematological disorders and acute kidney failure. The principal late ones were kidney failure and severe anemia. The postoperative mortality was 15.9%, and the principal causes were infection and then acute rejection. The survival at one, five, and ten years was 87.5%, 79.8%, and 79.8%, respectively. The survival results were not influenced by sex or age group. Conclusion: Our patients’ postoperative complications, mortality, and survival rates coincided with those reported by the ISHLT registry.